ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

9,137Medicare Part D Prescriptions Filled, Including Refills
$632K Total Retail Price of All Prescriptions
146 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
98% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
WARFARIN SODIUM 327 204
DONEPEZIL HCL 285 257
FAMOTIDINE 276 196
LEVOTHYROXINE SODIUM 259 194
FUROSEMIDE 249 220
NAMENDA 248 223
MIRTAZAPINE 214 171
SIMVASTATIN 204 126
POTASSIUM CHLORIDE 201 180
LEVEMIR FLEXPEN 197 141
AMLODIPINE BESYLATE 193 135
METOPROLOL TARTRATE 183 119
PRAVASTATIN SODIUM 154 109
NOVOLOG FLEXPEN 153 84
VALPROIC ACID 153 107
GABAPENTIN 152 137
OXYCODONE-ACETAMINOPHEN 148 141 S2
IBUPROFEN 147 143
OMEPRAZOLE 139 107
ZOLPIDEM TARTRATE 130 89
NOVOFINE AUTOCOVER 125 97
QUETIAPINE FUMARATE 119 90
DIGOXIN 116 116
HYDROCHLOROTHIAZIDE 111 73
ENALAPRIL MALEATE 101 54
METFORMIN HCL 100 73
LISINOPRIL 99 77
LACTULOSE 98 67
LEVETIRACETAM 93 35
TAMSULOSIN HCL 93 70
OLANZAPINE 92 79
RISPERIDONE 89 74
CLOPIDOGREL 84 65
METOPROLOL SUCCINATE 82 70
CITALOPRAM HBR 77 65
ESCITALOPRAM OXALATE 76 65
PAROXETINE HCL 71 42
ALBUTEROL SULFATE 69 62
OXYCODONE HCL 69 11 S2
PLAVIX 68 44
SERTRALINE HCL 68 68
DIOVAN 64 53
CARVEDILOL 60 47
FLUOCINONIDE 58 20
ABILIFY 57 33
LIDODERM 55 49
BACLOFEN 54 29
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 9, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.